Stock A8D AB SCIENCE
Add to a list
To use this feature you must be a member
Log inSign up

Ratings AB Science Deutsche Boerse AG

Equities

A8D

FR0010557264

Market Closed - Deutsche Boerse AG
Other stock markets
 07:04:49 28/06/2024 BST 		5-day change 1st Jan Change
1.1 EUR -2.31% Intraday chart for AB Science -6.94% -69.70%
06-28 AB Science: negative CHMP opinion for masitinib in ALS CF
06-03 AB Science: share price falls on resumption of trading CF

Strengths

  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
AB SCIENCE Stock AB Science
-69.70% 70.71M - -
MERCK KGAA Stock Merck KGaA
+7.39% 72.09B
A
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+15.93% 9.05B
A-
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-22.81% 4.4B
A-
YUHAN CORPORATION Stock Yuhan Corporation
+17.59% 4.39B
B-
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+25.93% 3.94B -
INDIVIOR PLC Stock Indivior PLC
+4.64% 2.1B
B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+9.09% 1.97B - -
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-36.86% 1.87B
C-
VELOXIS PHARMACEUTICALS A/S Stock Veloxis Pharmaceuticals A/S
-0.50% 1.64B - -
Investor Rating
-
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
-
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
-

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. AB Stock
  4. A8D Stock
  5. Ratings AB Science